Here, we summarize the current knowledge on eight promising drugs and natural
compounds that have been tested in the clinic: metformin, NAD+ precursors, glucagon-like …

GLP-1, a peptide hormone secreted from the gut, stimulating insulin and suppressing
glucagon secretion was identified as a parent compound for novel treatments of diabetes …

OBJECTIVE Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral
semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared …

In its 33 years, ADDR has published regularly on the po5tential of oral delivery of biologics
especially peptides and proteins. In the intervening period, analysis of the preclinical and …

Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as
monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 …

Background: Newer diabetes medications may have beneficial effects on mortality,
cardiovascular outcomes, and renal outcomes. Purpose: To evaluate the effectiveness …

Glucagon-like peptide-1 receptor agonists (GLP-1RA) are used for the treatment of type 2
diabetes. Whether clinically important responses and adverse events (AEs) are dependent …

Importance Glucagon-like peptide-1 (GLP-1) receptor agonist use is associated with
reduced mortality and improved cardiovascular outcomes in the general population with …

Glucagon-like peptide-1 receptor agonists (GLP-1RA) are effective agents for achieving
glycemic control. Oral semaglutide is the first oral formulation of a GLP-1RA to be approved …

Aims: The efficacy and safety of oral semaglutide, the first glucagon-like peptide-1 (GLP-1)
receptor agonist developed for oral administration for the treatment of type 2 diabetes, was …